Century Pacific Food, Inc.

Disclaimer: The research and recommendation below were generated by Claude Fable. Please treat this as one input for your own research — not as the sole basis for any decision to buy or sell a stock.

Last checked: July 19, 2026
Price: 31.6000
Trading status: Normal
Recommendation: Buy (quality compounder; capex squeeze near term)Buy
Committee call: Sell
Indices: PSEi

Analysis

CNPF - Century Pacific Food, Inc.

One-line summary: A Po family-controlled branded-foods compounder (Century Tuna, Argentina corned beef, coconut, pet food) growing revenue and earnings at double digits with an 18-20% ROE, trading at a below-its-own-history multiple, but mid-2026 free cash flow has turned negative and the dividend just got cut as capex doubles to fund an aggressive capacity build.

Snapshot


Reviewed	July 19, 2026
Index membership	PSEi
Price at review	P31.60 (July 17, 2026 close, last trading day; 52-week range P24.85-P41.30)
Recommendation	Buy (quality double-digit compounder; accumulate, but watch the capex-driven cash squeeze)
Market cap	P112B (3.54B shares)
Trailing P/E	~15.5x
Estimated forward P/E (2026)	~14.5x
Dividend	P1.15/share trailing (~3.64% yield), but the latest declaration was cut to P0.30 from P0.55 a year ago, ex-date July 21, 2026
P/B	~2.87x (was ~4.2x in 2021)
Debt	Conservative (D/E ~0.31)

Revenue trend: consistent double-digit growth

Revenue: P54.7B (2021), P62.3B (2022), P67.1B (2023), P75.5B (2024), P83.3B (2025), TTM P86.3B. Q1 2026 revenue grew 15% to P23.2B, net income grew 10% to P2.1B. The branded segment (marine, meat, milk, coconut and emerging categories, about 80% of sales: Century Tuna, 555, Blue Bay, Argentina corned beef, Angel, Snap) is volume-led, growing 11-13% as management holds prices to protect affordability for cost-conscious households. The OEM export segment (about 20% of sales: contract tuna and coconut manufacturing for global brands) is more cyclical and swung from roughly flat growth in slower stretches to 32% growth in Q1 2026 as tuna markets and coconut demand recovered. This is a genuinely growing business, unlike URC's flat-to-declining profit or GMA7's structural decline.

Margin pressure: expiring tax incentives, not a demand problem

Gross margin contracted about 100 basis points to 25.1% in Q1 2026 on higher input costs, but favorable foreign exchange on dollar-denominated exports (about 25% of sales) offset most of it, keeping operating margin roughly flat to slightly up. Net margin still slipped (about 9.1% in Q1 2026 versus 9.5% a year earlier) because the effective tax rate jumped to 19.4% from 15.6% as tax incentives on some plants expire, a structural headwind rather than a one-off. Management held off on price increases until late May 2026 despite the cost pressure, then implemented an average 3% hike, still below the Philippines' 6.8% inflation rate (May 2026). Executive Chairman Christopher Po said (July 1, 2026) the company is still evaluating further increases, and that easing oil prices and de-escalating Middle East tensions could reduce the need for them in the second half.

Growth drivers: coconut, dairy, pet food and plant-based, funded by a capex surge

Management is guiding coconut, pet food and plant-based products (the "emerging categories") to 30-40% annual growth, well ahead of the mature marine and meat core. To fund that, 2026 capex guidance is P8-9B, roughly double 2025's already-elevated P4.1B, aimed at expanding capacity in coconut, dairy, tuna OEM export and new pet food lines. CEO Teodoro Alexander Po has framed it as a capacity constraint, not a discretionary bet: the company has grown in the teens for five years and is "starting to hit the capacity on a number of the plants." In August 2025, Century Pacific North America also bought the Loma Linda and Tuno plant-based brands from Atlantic Natural Foods for under $10M, a small bolt-on that adds a 135-year-old US shelf-stable plant-based line to the existing UnMeat platform sold through Walmart, Albertsons and others. On July 1, 2026, management reaffirmed the P8-9B capex guidance despite the earthquake and Middle East headwinds noted below, framing the spend as demand-driven rather than discretionary, and said it expects the second half of 2026 to perform similarly to or slightly better than the first half, with full-year revenue and profit growth still targeted in the double digits.

Risks: earthquake disruption and geopolitical cost pressure

A magnitude 7.8 earthquake struck General Santos City on June 8, 2026, forcing Century Pacific (and rival Alliance Select) to pause tuna and coconut canning operations there; two people died when a warehouse wall collapsed at one of the company's facilities. Operations were reported near full recovery by early July, but some OEM export revenue was deferred into the second half. Separately, management had flagged Middle East tensions as a headwind for the second half of 2026 without fully quantifying the mechanism (likely shipping and input costs). By July 1, 2026, Christopher Po described that impact as starting to wind down and pointed to easing oil prices as a tailwind, though general global trade uncertainty remains. That's a genuine improvement from the prior read, but it's management's own characterization; it needs a quarter of actual results, not just commentary, before being treated as resolved. Neither risk looks thesis-breaking on its own, but both are real, current, and worth checking again next quarter.

Dividend sustainability: still low payout, but the trend just reversed

Semi-annual dividend history: P0.36 total (2022, including a P0.18 special), P0.40 (early 2023), P0.48 + P0.48 (2024), P0.55 + P0.55 (2025), then P0.60 declared in March 2026, followed by a cut to P0.30 declared June 30, 2026 (ex-date July 21, payable August 10, 2026), about 45% lower than the immediately prior declaration and roughly 18% below the year-ago second-half payout. Payout ratio is still low on a trailing basis, about 27-29% of net income (P1.9-2.1B in dividends paid against P6.3-7.3B net income), and historically well covered by operating cash flow. The catch: trailing twelve-month free cash flow has gone negative (about -P0.7B) as capex more than doubles, so the dividend is currently being funded out of the balance sheet and operating cash flow rather than free cash flow. Debt/equity of 0.31 gives room to absorb this, but a management team funding an P8-9B capex year rarely also grows the dividend, and the July 2026 cut confirms cash is being redirected to growth capex rather than returned to shareholders this cycle.

ROE: high, stable, and not leverage-flattered

ROE: 20.18% (2021), 18.63% (2022), 18.11% (2023), 18.46% (2024), 18.89% (2025), about 19.4% on a trailing basis. Debt/equity has stayed conservative throughout (0.15-0.33), so this is a genuine, brand-driven return on equity, not a leverage effect. It is the best ROE among the PH consumer names reviewed so far in this wiki; for comparison, URC's ROE has slid to 8.8%.

Free cash flow: swinging negative as the capex build accelerates

Operating cash flow: P2.4B (2022), P8.3B (2023), P8.0B (2024), P4.5B (2025), P3.6B trailing twelve months (down sharply from the 2023-2024 peak). Capex: P1.4B (2022), P1.5B (2023), P2.3B (2024), P4.1B (2025), P4.3B trailing twelve months, guided to P8-9B for full-year 2026, which would be the highest capex year in the company's history as a listed entity. Free cash flow: P1.0B (2022), P6.8B (2023), P5.7B (2024), P0.4B (2025), about -P0.7B trailing twelve months. The direction is deliberate: the company is building capacity ahead of demand in coconut, dairy, tuna OEM and pet food. This is an investing phase, not a harvesting one, and the balance sheet can carry it given low leverage, but if operating cash flow doesn't step up alongside the new capacity, free cash flow could stay negative through the build-out.

Capital allocation: family-controlled, disciplined bolt-ons, growth capex over dividends right now

Century Pacific Group, Inc., the private parent itself majority-owned by the Po family through Zephryn Holdings (about 45.7% of CPGI), holds roughly 72% of listed CNPF. Day-to-day management stays with the Po family: Christopher Po as Executive Chairman, Teodoro Alexander Po as President and CEO. The M&A track record favors small, complementary bolt-ons over large bets: the under-$10M Loma Linda/Tuno acquisition added a legacy US plant-based brand to the existing UnMeat platform rather than a transformative deal. The clear current priority is organic capex (P8-9B for 2026) over dividends or buybacks, funding the coconut, dairy, pet food and tuna OEM export capacity management is counting on for 30-40% growth in those categories. No buyback program is in place. This is a growth-reinvestment allocator, the opposite of URC's post-divestiture story of professional management with middling returns so far; the test over the next few quarters is whether the incremental capex earns anywhere near the company's existing ~19% ROE.

Verdict at P31.60 (July 19, 2026)

Buy, sized for an investment-phase business rather than a harvest-phase one. The core case: an 18-20% ROE consumer-brands compounder growing revenue in the low-to-mid teens, trading at roughly 15.5x trailing and 14.5x forward earnings and about 2.87x book, both still below its own 2021-2024 range (P/E 18-23x, P/B up to 4.2x). That is a reasonable entry price for the growth and returns on offer. The real, current risks are the negative trailing free cash flow and the July 2026 dividend cut, both direct consequences of capex more than doubling to P8-9B this year, plus the rising effective tax rate as incentives expire and near-term noise from the Mindanao earthquake. No fresh company news broke in the week since the last review; management's July 1, 2026 commentary (a modest 3% price hike, easing oil prices, de-escalating Middle East tensions) still hasn't been confirmed by an actual quarter of results. None of this breaks the thesis by itself given debt/equity of only 0.31 and operating cash flow still covering the dividend even though free cash flow does not, but this is not a buy-and-forget name. The next two to three quarters need to show the capex is converting into the promised 30-40% growth in coconut, dairy and pet food, and that free cash flow recovers once the build tapers.

No buy or sell trigger fired this review: price drifted slightly lower to P31.60 (still above the P26-29 buy-trigger range), free cash flow is still negative, ROE held at 19.4%, debt/equity is unchanged at 0.31, and the branded segment kept growing 11-13%. Worth flagging: the committee below has now gone from split (2 bearish, 3 neutral) to unanimously bearish week over week on the same underlying facts, which is a widening gap against this page's Buy call. That shift is being driven by how much weight each lens puts on the negative free cash flow and the dividend cut rather than any new information, so it is a read on how the existing facts are aging, not a new data point in itself.

What would change the call:

Buy trigger: price pulls back into the P26-29 range (closer to the 52-week low) without any change to the growth or ROE story; or free cash flow turns positive again as 2026 capex tapers, confirming this is an investment phase rather than a structural cash problem; or General Santos operations post a clean quarter with no further earthquake-related revenue deferrals.
Sell trigger: a second consecutive dividend cut (would confirm capital allocation stress rather than a one-time reallocation to capex); ROE falling below 15% (would mean the new capacity isn't earning its keep); debt/equity rising past roughly 0.7 to fund capex (would mean the balance sheet, not cash flow, is funding growth); or branded-segment volume growth stalling below high single digits (would undercut management's "structural, not cyclical" domestic demand thesis).

Analysis, not financial advice.

Committee review (July 19, 2026)

The five lenses judged the facts above independently, each strictly inside its own framework, with no recommendation shown to them in advance.

Lens	Signal	Confidence	Core argument
Ben Graham	Bearish	72	Graham's number (P/E x P/B) reads about 15.5 x 2.87 = 44.5, roughly double his 22.5 ceiling. Debt/equity of 0.31 is conservative, but the margin of safety is thin: free cash flow just went negative (about -P0.7B TTM) as capex doubles to P8-9B, and the 45% June 2026 dividend cut breaks the steady-payout record Graham requires as evidence of durable earnings power.
Warren Buffett	Bearish	64	ROE has stayed strong (18-20%) on low leverage, which looks like a moat working, but owner earnings tell the real story: free cash flow collapsed from P6.8B (2023) to P0.4B (2025) to about -P0.7B TTM as capex is set to nearly double, while margins compress. A 45% dividend cut alongside that capex surge reads as cash strain, not disciplined reinvestment, at a P/B of 2.87x.
Michael Burry	Bearish	70	Free cash flow has gone negative on a trailing basis (-P0.7B, down from P6.8B in 2023) while capex guidance conveniently doubles under a "capacity-constrained" narrative management hasn't proven out. The dividend was raised to P0.60 in March 2026 then slashed 45% to P0.30 three months later, exactly the kind of gap between presented confidence and balance-sheet reality that should be distrusted.
Nassim Taleb	Bearish	58	Skin in the game is strong (Po family, ~72% ownership) but the balance sheet shows fragility building: free cash flow is negative while capex nearly doubles, funded against a single concentrated production node a magnitude-7.8 earthquake just proved can halt output and kill workers. The expiring tax incentives (rate up to 19.4% from 15.6%) are a structural, irreversible margin hit, not noise.
Stanley Druckenmiller	Bearish	68	No clear catalyst for a position: the dividend just got cut about 45%, free cash flow is negative as capex doubles, and the tax-incentive rollback is structural, not cyclical. Price hikes of 3% trailing 6.8% inflation show pricing power is capped. The only bull case (earthquake recovery, Middle East de-escalation) rests on management's own unconfirmed framing, not a realized catalyst.

Conferred call: Sell (5 bearish, 0 neutral, 0 bullish). This is a harder disagreement with the page's Buy recommendation than last week's Hold: on the same underlying facts (no material news broke this week), all five lenses now weight the negative trailing free cash flow, the 45% dividend cut, and the structural tax-rate increase heavily enough to turn bearish, where three were neutral seven days ago. None of the page's own explicit sell triggers fired (ROE, debt/equity, and branded-segment growth are all unchanged), so the Recommendation stays Buy, but the committee's unanimous shift is a signal in its own right per the rulebook's warning against treating "cheap relative to its own history" as a green light once cash generation has turned negative; it argues for tightening the size of any new buy rather than ignoring it. Shared flip trigger: All five lenses converge on the same test: free cash flow turning solidly and sustainably positive (not just operating cash flow) as the 2026 capex build tapers.

Review history

Date	Price	Recommendation
July 19, 2026	31.60	Buy (quality compounder; accumulate, watch the capex-driven cash squeeze); committee conferred Sell
July 12, 2026	32.50	Buy (quality compounder; accumulate, watch the capex-driven cash squeeze); committee conferred Hold
July 10, 2026	31.75	Buy (quality compounder; accumulate, watch the capex-driven cash squeeze)